OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 3,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 9.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,068 shares of the company’s stock after selling 3,000 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.06% of Mineralys Therapeutics worth $346,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in shares of Mineralys Therapeutics in the fourth quarter worth $48,000. China Universal Asset Management Co. Ltd. increased its holdings in Mineralys Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock worth $130,000 after buying an additional 989 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Mineralys Therapeutics in the 4th quarter worth about $145,000. EntryPoint Capital LLC bought a new position in Mineralys Therapeutics during the 4th quarter valued at about $154,000. Finally, AlphaQuest LLC boosted its holdings in shares of Mineralys Therapeutics by 2,637.8% during the 4th quarter. AlphaQuest LLC now owns 15,222 shares of the company’s stock valued at $187,000 after acquiring an additional 14,666 shares during the last quarter. 84.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

MLYS has been the subject of several research reports. Guggenheim reissued a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. HC Wainwright reiterated a “buy” rating and set a $42.00 target price on shares of Mineralys Therapeutics in a research note on Tuesday. Finally, The Goldman Sachs Group lowered their price target on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, February 13th.

Insider Transactions at Mineralys Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 1,296,296 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were purchased at an average price of $13.50 per share, with a total value of $17,499,996.00. Following the completion of the purchase, the director now directly owns 4,280,051 shares of the company’s stock, valued at $57,780,688.50. This represents a 43.45% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $12.06, for a total value of $129,729.42. Following the transaction, the chief financial officer now directly owns 215,340 shares in the company, valued at approximately $2,597,000.40. The trade was a 4.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 93,213 shares of company stock worth $1,360,567 in the last 90 days. 25.56% of the stock is currently owned by insiders.

Mineralys Therapeutics Stock Down 0.5%

Mineralys Therapeutics stock opened at $15.11 on Thursday. Mineralys Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $18.38. The company has a market cap of $980.28 million, a P/E ratio of -4.15 and a beta of -0.30. The business has a 50-day simple moving average of $14.26 and a two-hundred day simple moving average of $12.46.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.23. Research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.